Repligen Co. (NASDAQ:RGEN) Insider Sells $815,784.57 in Stock

Repligen Co. (NASDAQ:RGENGet Rating) insider Christine Gebski sold 3,357 shares of Repligen stock in a transaction that occurred on Thursday, August 4th. The stock was sold at an average price of $243.01, for a total value of $815,784.57. Following the transaction, the insider now owns 30,735 shares of the company’s stock, valued at $7,468,912.35. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Repligen Stock Performance

Repligen stock opened at $246.27 on Friday. Repligen Co. has a 52 week low of $137.21 and a 52 week high of $327.32. The stock has a market capitalization of $13.40 billion, a P/E ratio of 88.91 and a beta of 1.07. The stock has a fifty day moving average of $175.20 and a 200-day moving average of $174.08.

Repligen (NASDAQ:RGENGet Rating) last posted its quarterly earnings results on Tuesday, August 2nd. The biotechnology company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.19. Repligen had a return on equity of 11.18% and a net margin of 20.47%. The company had revenue of $207.63 million during the quarter, compared to analysts’ expectations of $189.06 million. During the same quarter in the previous year, the firm earned $0.79 EPS. Repligen’s revenue was up 27.4% on a year-over-year basis. On average, research analysts forecast that Repligen Co. will post 3.21 earnings per share for the current year.

Hedge Funds Weigh In On Repligen

A number of institutional investors have recently modified their holdings of the business. HM Payson & Co. acquired a new position in Repligen in the 4th quarter worth about $26,000. Confluence Wealth Services Inc. acquired a new position in Repligen in the 4th quarter worth about $27,000. Sageworth Trust Co of South Dakota acquired a new position in Repligen in the 4th quarter worth about $46,000. Harding Loevner LP increased its holdings in Repligen by 121.3% in the 1st quarter. Harding Loevner LP now owns 177 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 97 shares in the last quarter. Finally, Rise Advisors LLC acquired a new position in Repligen in the 4th quarter worth about $52,000. Institutional investors and hedge funds own 86.82% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. UBS Group assumed coverage on Repligen in a research note on Wednesday, July 20th. They issued a “buy” rating and a $213.00 price target for the company. SVB Leerink boosted their price target on Repligen from $220.00 to $250.00 and gave the company an “outperform” rating in a research note on Wednesday. Stephens boosted their price target on Repligen from $220.00 to $275.00 and gave the company an “overweight” rating in a research note on Wednesday. Craig Hallum reduced their price target on Repligen from $286.00 to $274.00 in a research note on Thursday, April 28th. Finally, KeyCorp boosted their price target on Repligen from $245.00 to $260.00 and gave the company an “overweight” rating in a research note on Wednesday. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Repligen has a consensus rating of “Moderate Buy” and a consensus price target of $276.00.

Repligen Company Profile

(Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Featured Stories

Insider Buying and Selling by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.